A Feb. 21 Personalized Medicine Coalition report says 12 personalized treatments and seven diagnostics approved or cleared by FDA in 2019 will improve patient care and address root causes of rare diseases, expand treatment for cancer patients, and target therapies to people who respond.
Boehringer Ingelheim and Trutino Biosciences entered into a licensing agreement based on Trutino's innovative On-Demand-Cytokine platform.
Many patients with rare, fast-growing neuroendocrine tumors respond well to a combination of ipilimumab and nivolumab, according to the first peer-reviewed publication out of DART, a rare cancer clinical trial.
The best approach for surgeons to identify malnourished cancer patients before they have a cancer operation may be related to the cancer type, according to an article published in the Journal of the American College of Surgeons.
Jennifer Cullen was named associate director for Cancer Population Sciences at The Case Comprehensive Cancer Center.
Aaron Gerds was named medical director of the Clinical Research Office at Case Comprehensive Cancer Center.
Lewis C. Cantley, Leslie Bernstein, and Ching-Hon Pui received the 2020 Medal of Honor award from the American Cancer Society.
Last year, FDA approved 11 new drugs and biologics as well as 30 supplemental indications and four biosimilars, according to commentary by FDA officials published in Nature Reviews.
The FDA Oncologic Drugs Advisory Committee Feb. 26 voted down a vascular-targeted photodynamic therapy for early-stage, low-risk prostate cancer and, in a narrow vote, recommended approval for a combination of a VEGF receptor 2 antagonist and an EGFR-targeting tyrosine kinase inhibitor for front-line treatment of EGFR-positive non-small cell lung cancer.
The FY20 Defense Appropriations Act provides funding to the Department of Defense Lung Cancer Research Program to support innovative, high-impact lung cancer research.
